PubMed:27172902 / 766-1053 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T5","span":{"begin":0,"end":287},"obj":"Sentence"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}

{"project":"LitCoin-entities","denotations":[{"id":"11296","span":{"begin":30,"end":33},"obj":"GeneOrGeneProduct"},{"id":"11297","span":{"begin":44,"end":53},"obj":"ChemicalEntity"},{"id":"11298","span":{"begin":92,"end":97},"obj":"GeneOrGeneProduct"},{"id":"11299","span":{"begin":135,"end":143},"obj":"GeneOrGeneProduct"},{"id":"11300","span":{"begin":148,"end":153},"obj":"GeneOrGeneProduct"},{"id":"11301","span":{"begin":204,"end":209},"obj":"GeneOrGeneProduct"},{"id":"11302","span":{"begin":214,"end":222},"obj":"GeneOrGeneProduct"},{"id":"11303","span":{"begin":239,"end":248},"obj":"ChemicalEntity"}],"attributes":[{"id":"A17","pred":"db_id","subj":"11296","obj":"NCBIGene:13982"},{"id":"A18","pred":"db_id","subj":"11297","obj":"MESH:D002945"},{"id":"A19","pred":"db_id","subj":"11298","obj":"NCBIGene:16153"},{"id":"A20","pred":"db_id","subj":"11299","obj":"NCBIGene:26416"},{"id":"A21","pred":"db_id","subj":"11300","obj":"NCBIGene:18033"},{"id":"A22","pred":"db_id","subj":"11301","obj":"NCBIGene:21926"},{"id":"A23","pred":"db_id","subj":"11302","obj":"NCBIGene:16185"},{"id":"A24","pred":"db_id","subj":"11303","obj":"MESH:D002945"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T26","span":{"begin":44,"end":53},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":73,"end":81},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":92,"end":97},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":98,"end":108},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":117,"end":127},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":135,"end":143},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":239,"end":248},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":249,"end":257},"obj":"GeneOrGeneProduct"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T14","span":{"begin":44,"end":53},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":92,"end":97},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":135,"end":143},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":239,"end":248},"obj":"GeneOrGeneProduct"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T8","span":{"begin":30,"end":33},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":92,"end":97},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":135,"end":143},"obj":"GeneOrGeneProduct"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T4","span":{"begin":62,"end":65},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":283,"end":286},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0010155"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0010155"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T11","span":{"begin":44,"end":53},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":239,"end":248},"obj":"ChemicalEntity"}],"attributes":[{"id":"A11","pred":"ID:","subj":"T11","obj":"D002945"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_27899"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D002945"},{"id":"A14","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_27899"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T13","span":{"begin":239,"end":248},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":44,"end":53},"obj":"ChemicalEntity"},{"id":"T92895","span":{"begin":135,"end":143},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":92,"end":97},"obj":"GeneOrGeneProduct"},{"id":"T5090","span":{"begin":30,"end":33},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A14","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_27899"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D002945"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_27899"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D002945"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}

{"project":"Inflammaging","denotations":[{"id":"T5","span":{"begin":0,"end":287},"obj":"Sentence"},{"id":"T5","span":{"begin":0,"end":287},"obj":"Sentence"}],"text":"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs."}